{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:08:12Z","timestamp":1784300892692,"version":"3.55.0"},"reference-count":39,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl J Gynecology &amp; Obste"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Menopause is frequently associated with different symptoms and signs, such as vasomotor symptoms (VMSs), which can affect women's quality of life. While hormonal therapy is considered the traditional and most used medication for controlling these VMSs associated with menopause, neurokinin (NK) receptor antagonists resemble a novel, promising generation of medications that provide fewer adverse events compared to hormonal therapy. Elinzanetant is the first drug that can act on both NK\u20101 and 3 receptors by selectively antagonizing them. It has also been developed for the management of moderate\u2010to\u2010severe VMSs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We aim to investigate the effectiveness and safety of elinzanetant compared to placebo in the management of moderate and severe VMSs that are associated with postmenopausal women.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We conducted a search of four databases (PubMed, Cochrane, Web of Science, and Scopus) using the following search strategy: ([Elinzanetant) OR [NT\u2010814] OR [BAY 3427080] OR (NK Receptor Antagonist]) AND ([Menopausal Symptoms] OR [Flashes Vasomotor Symptoms] OR (VMS)) with no search restrictions or filters applied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Selection Criteria<\/jats:title>\n                    <jats:p>We included randomized controlled clinical trials (RCTs) comparing elinzanetant to placebo in post\u2010menopausal women suffering from frequent moderate\u2010to\u2010severe VMSs that reported both efficacy and safety outcomes. We used a uniform Google Sheet designed to collect data from our included RCTs. After data collection, we used Review Manager Software (RevMan) V.5.4.1. to perform all the analyses and plots using a risk ratio (RR) with a 95% confidence interval (CI) for dichotomous outcomes and mean difference (MD) with a 95% CI for continuous outcomes. We conducted risk of bias assessment using Risk of Bias Assessment tool\u20102 (ROB2).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We included five RCTs in our review with 1699 participants. Our results reported that elinzanetant demonstrated a statistically significant difference in reducing both frequency and severity of VMSs at week 4 compared to placebo (MD\u2009=\u2009\u22122.75, 95% CI: [\u22123.83, \u22121.67],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.00001; MD\u2009=\u2009\u22120.29, 95% CI: [\u22120.35, \u22120.22],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.00001, respectively). These results were maintained at week 12 for both frequency (MD\u2009=\u2009\u22122.30, 95% CI: [\u22123.00, \u22121.59],\n                      <jats:italic>P\u2009&lt;<\/jats:italic>\n                      \u20090.00001) and severity (MD\u2009=\u2009\u22120.35, 95% CI: [\u22120.43, \u22120.28],\n                      <jats:italic>P\u2009&lt;<\/jats:italic>\n                      \u20090.00001). Compared to placebo, elinzanetant was associated with a higher incidence of treatment\u2010emergent adverse events (TEAEs) (RR\u2009=\u20091.12, 95% CI: [1.03, 1.22],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01), TEAEs causing permanent discontinuation of the study drug (RR\u2009=\u20092.18, 95% CI: [1.45, 3.28],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0002), drug\u2010related TEAEs (RR\u2009=\u20091.92, 95% CI: [1.53, 2.41],\n                      <jats:italic>P\u2009&lt;<\/jats:italic>\n                      \u20090.00001), headache (RR\u2009=\u20092.19, 95% CI: [1.38, 3.49],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0009), somnolence (RR\u2009=\u20092.96, 95% CI: [1.42, 6.17],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.004), and fatigue (RR\u2009=\u20093.39, 95% CI: [1.77, 6.49],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0002). However, no statistically significant difference was observed in the incidence of serious TEAEs (RR\u2009=\u20091.70, 95% CI: [0.82, 3.54],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.15).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Elinzanetant showed significant efficacy in reducing both the frequency and severity of VMSs associated with post\u2010menopausal women at different time points, while concurrently improving outcomes associated with women's quality of life. While elinzanetant was associated with a higher incidence of non\u2010serious adverse events such as headache, somnolence, and fatigue, which led to more treatment discontinuations, it did not increase the risk of serious adverse events compared to placebo, indicating an acceptable safety profile. Conclusively, our results indicate that elinzanetant represents a promising alternative for VMS management; however, it should not replace the clinical assessment of eligibility for hormone therapy. Further studies are required to confirm its long\u2010term safety and sustained effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:styled-content style=\"fixed-case\">PROSPERO<\/jats:styled-content>\n                      Registration\n                    <\/jats:title>\n                    <jats:p>Our study was registered on PROSPERO on September 20, 2024, with ID CRD42024593052.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ijgo.70878","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T04:03:47Z","timestamp":1773029027000},"page":"579-598","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Elinzanetant: Efficacy and safety in the management of vasomotor symptoms in postmenopausal women, a systematic review and meta\u2010analysis with grading of recommendations assessment, development, and evaluation assessment"],"prefix":"10.1002","volume":"174","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6667-0021","authenticated-orcid":false,"given":"Eslam","family":"Afifi","sequence":"first","affiliation":[{"name":"Faculty of Medicine Benha University  Benha Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7722-6863","authenticated-orcid":false,"given":"Rahma","family":"Abdelaziz Ismail","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Benha University  Benha Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8310-4124","authenticated-orcid":false,"given":"Asmaa","family":"Ashraf Aldbash","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Benha University  Benha Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1023-0232","authenticated-orcid":false,"given":"Ahmed","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Benha University  Benha Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3971-4148","authenticated-orcid":false,"given":"Ahmed","family":"Osama","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Benha University  Benha Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7452-2062","authenticated-orcid":false,"given":"Rabie","family":"Azzam","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Benha University  Benha Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4051-5941","authenticated-orcid":false,"given":"Ahmed","family":"Ayman","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Benha University  Benha Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4201-0826","authenticated-orcid":false,"given":"Mohamed","family":"Aranda","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Benha University  Benha Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5200-6138","authenticated-orcid":false,"given":"Rahmah","family":"Sameh Shaheen","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Benha University  Benha Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00477.2022"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/13697137.2018.1430131"},{"key":"e_1_2_10_4_1","first-page":"979","article-title":"Sleep disturbance during the menopausal transition in a multi\u2010ethnic community sample of women","volume":"31","author":"Kravitz HM","year":"2008","journal-title":"Sleep"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ogc.2011.05.006"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000001793"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa764"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000001054"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.52054\/FVVO.15.4.102"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2018-00934"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmu009"},{"key":"e_1_2_10_12_1","unstructured":"Swissmedic.\u00a9 Copyright. VeozaTM Filmtabletten (Fezolinetantum) n.d.2019Accessed October 11. 2024https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/humanarzneimittel\/authorisations\/new\u2010medicines\/veozatm\u2010filmtabletten\u2010fezolinetantum.html"},{"key":"e_1_2_10_13_1","unstructured":"Commissioner of the FDA.Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by Menopause. FDA 2024. Accessed October 11 2024.https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010novel\u2010drug\u2010treat\u2010moderate\u2010severe\u2010hot\u2010flashes\u2010caused\u2010menopause"},{"key":"e_1_2_10_14_1","unstructured":"Veoza | European Medicines Agency (EMA).2023Accessed October 11 2024.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/veoza"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2025.4421"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.14618"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000001500"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000002138"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31823608ca"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_10_22_1","unstructured":"EndNote\u2014The best citation & reference management tool. EndNote. n.d. Accessed November 17 2024.https:\/\/endnote.com\/"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"e_1_2_10_26_1","unstructured":"RevMan: Systematic review and meta\u2010analysis tool for researchers worldwide | Cochrane RevMan. n.d. Accessed November 17 2024.https:\/\/revman.cochrane.org\/info"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yfrne.2013.07.003"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000036592"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000002281"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2025.108220"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2025.01.050"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000005812"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.2147\/NSS.S125807"},{"key":"e_1_2_10_35_1","unstructured":"Intro to PROMIS. n.d. Accessed October 16 2024.https:\/\/www.healthmeasures.net\/explore\u2010measurement\u2010systems\/promis\/intro\u2010to\u2010promis"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1389-9457(00)00065-4"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(89)90047-4"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02787-z"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000002354"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s43043-025-00231-y"}],"container-title":["International Journal of Gynecology &amp; Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijgo.70878","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijgo.70878","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijgo.70878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:52:26Z","timestamp":1784299946000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1002\/ijgo.70878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1002\/ijgo.70878"],"URL":"https:\/\/doi.org\/10.1002\/ijgo.70878","archive":["Portico"],"relation":{},"ISSN":["0020-7292","1879-3479"],"issn-type":[{"value":"0020-7292","type":"print"},{"value":"1879-3479","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"2025-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}